Introduction {#s1}
============

Methylmalonic acidemia (MMA) is a rare genetic metabolic disease, and most of its cases are autosomal recessive. It is estimated that the incidence of MMA in Western populations ranges from 1:48,000 to 1:61,000 births, and the overall incidence of isolated MMA is believed to be \~1:50,000. In some populations across the world, the incidence is much higher ([@B1]). A large amount of methylmalonic acid accumulates in patients with MMA due to the deficiency of MCM or the synthesis of its active cofactor, adenosylcobalamin (AdoCbl). Defects in cobalamin (vitamin B12) metabolism may also manifest as homocystinuria (called combined MMA) ([@B2]). Most severe, early-onset MMA cases are caused by mutations in the MUT gene located on chromosome 6p21 and are called isolated MMA ([@B3]). To date, 272 different MUT mutations have been discovered, most of which are missense or nonsense mutations ([@B4]).

MMA is one of the most frequent organic acidurias. Propionic acidemia (PA), another inborn errors of metabolism, has defects in enzyme propionyl-CoA carboxylase (PCC) which also lead to accumulation of toxic metabolites by disrupting the normal amino acid metabolism ([@B5]). The severity of illness of patients with isolated MMA varies. For patients with severe cases, the onset of MMA begins in the neonatal or infancy period, with recurrent metabolic decompensation, or metabolic crisis. The manifestations lack specificity in clinical symptoms, but the most common symptoms are vomiting, metabolic acidosis, and high blood ammonia hyperammonemia which is usually associated with decreased levels of glutamine ([@B6]). If without prompt identification and appropriate management, one can become progressively encephalopathic, and ultimately progresses to coma and even death. The mortality of mut MMA was nearly 60% or even higher in the 1980s and improved only slightly, to about 40%, by the first decade in the 2000s ([@B7]--[@B10]). Currently, conventional therapies are symptom-based treatment and dietary and nutritional management. The mainstay of nutrition therapy is low protein intake through limitation of the propionic acid precursor amino acids, isoleucine, valine, methionine, and threonine, to reduce elevated concentrations of metabolites and by supplementing with precursor-free infant amino formula to ensure nutritional requirements are met. Administration of L-carnitine (to help enhance the elimination of propionyl group), sodium bicarbonate, and vitamin B12 is also included ([@B1]). However, patients with isolated MMA often have earlier and more severe clinical manifestations, most of which are coupled with long-term complications involving multiple organs and frequent hospitalization due to recurrent metabolic decompensation ([@B11], [@B12]). MMA continues to cause significant morbidity and mortality due to acute and chronic multisystemic damages such as severe metabolic stroke events which may be associated with basal ganglia necrosis. Since prognosis of this disorder is strongly influenced by the time of metabolic decompensation and end-organ injuries, improving metabolic stability, and possibly change the natural history of MMA is significant. Other treatments are urgently needed to improve the long-term survival.

Since most metabolic conversion of MMA occurs in the liver, liver transplant (LT) can help patients regain enzyme activity and improve metabolic capacity ([@B13]). Since LT was performed for a patient with MMA for the first time in 1997 ([@B14]), LT and combined kidney-liver transplant (CKLT) have been increasingly used to treat MMA cases where frequent metabolic decompensation cannot be relieved by diet therapy and medication and have successfully saved many lives. These results emphasize the urgent need to better understand this kind of therapeutic strategy. In our review, we provide a literature overview of MMA patients undergoing LT or CKLT to explore the value of LT in the treatment of MMA.

Methods {#s2}
=======

The literature about MMA patients undergoing LT/CKLT published since 2006 was reviewed in PubMed Database. The key words used include methylmalonic acidemia, methylmalonic acid, MCM deficiency, liver transplantation, and combined liver-kidney transplantation. Age at transplant, procedure and follow-up period were reviewed in the articles. Data on the onset frequency of metabolic decompensation or crisis time, MMA levels in the plasma and urine, protein diet, neurological damage, renal insufficiency, and developmental delay before and after transplantations were analyzed to better evaluate the clinical value of this procedure for MMA. Research of animal model and review article were excluded. Papers with irrelevant content to the topic we focused were also not included.

Results {#s3}
=======

We summarized the characteristics of reported patients with MMA undergoing LT/CKLT since 2006 ([Table 1](#T1){ref-type="table"}). All patients were alive when the literature was published, except for one patient who died of sepsis on postoperative day 44 ([@B15]).

###### 

Outcomes of LT/CKLT for patients with MMA.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**         **Age at Tx**            **Procedure**                                    **Follow-up**          **Metabolic decompensation/crisis time**   **MMA level (P/CSF: nmol/mL U:** **μmol/mmol Cr)**   **Dietary protein (g/kg/d)**                **Neurological damage/ DQ**   **Renal dysfunction (eGFR:mL/min/1.73 m**^****2****^   **Developmental delay/SD of height**                                                                                                                                                                                                                                                                                                            
  ---------------------- ------------------------ ------------------------------------------------ ---------------------- ------------------------------------------ ---------------------------------------------------- ------------------------------------------- ----------------------------- ------------------------------------------------------ -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------- ------ --------------------------------------------- --------------------------------------- ----------
  Kaplan\                19 m                     OLT                                              10 y                   Y                                          Y\                                                   P:574 ± 431                                 P:220 ± 79                    1.7                                                    NA                                     Increased subarachnoid space                                                                                                         Acute lesion in\                                                       N      eGFR = 77                                     Between the 25th and 50th percentiles   −2SD
  et al. (27)                                                                                                                                                        (only twice)                                                                                                                                                                                                                                                                                                                                                      right globus pallidus, then resolved[^&^](#TN1){ref-type="table-fn"}                                                                                                

                                                                                                                                                                                                                          U:9307 ± 4923                               U:3656 ± 2271                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                          CSF: 1103                                   CSF:901 ± 263                                                                                                                                                                                                                                                                                                                                                                                                                        

  Mc Guire\              5 y                      CKLT\                                            10 m                   Y                                          N                                                    P:20--2591                                  P:25--525                     1.95                                                   NA                                     Y (cerebellar stroke)                                                                                                                Y                                                                      Y      N                                             Failure to\                             NA
  et al. (21)                                     (OLT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            thrive                                  

                                                                                                                                                                                                                          U:1101--13962                               U:116--1895                                                                                                                                                                                                                                                                                                                                                                                                                          

  Chen\                  0.9--2.1 y               LDLT\                                            0.2--7.7 y             2.73/y                                     0.08/y                                               P:87.5--204                                 P:63.2--87                    0.66--1.00                                             1.37--2.80                             NA                                                                                                                                   NA                                                                     N      N                                             Development all continued               
  et al. (19)                                     (*n* = 4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Morioka\               7--90 m                  LDLT\                                            19--53 m               Y                                          N                                                    P:268.0                                     P:99.4                        1.0                                                    3.0                                    The global cognitive index of the McCarthy scale and the Denver development quotient were improved but did not reach normal values   N                                                                      N      −2                                            −2                                      
  et al. (15) Kamei\                              (*n* = 7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  et al. (16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                          P:47.0                                      P:59.2                        1.2                                                    2.5                                                                                                                                                                                                                                                N      N                                             −2                                      −2

                                                                                                                                                                                                                          P:143.0                                     P:36.4                        0.7                                                    2.5                                                                                                                                                                                                                                                N      N                                             −3.14                                   −2

                                                                                                                                                                                                                          P:39.0                                      P:29.3                        2.0                                                    3.0                                                                                                                                                                                                                                                N      N                                             −2                                      −1

                                                                                                                                                                                                                          P:375.0                                     P:87.8                        1.0                                                    2.5                                                                                                                                                                                                                                                N      N                                             −1.3                                    −0.6

                                                                                                                                                                                                                          P:1970.0                                    P:232.0                       --[^\#^](#TN2){ref-type="table-fn"}                    --                                                                                                                                                                                                                                                 Y      --                                            --                                      --

                                                                                                                                                                                                                          P:166.0                                     P:13.8                        1.5                                                    2.5                                                                                                                                                                                                                                                N      N                                             −3                                      −2

                                                  LDLT (*n* = 3)                                                                                                                                                          P:278.0                                     P:59.6                        NA                                                     NA                                     NA                                                                                                                                   NA                                                                     N      N                                             NA                                      NA

                                                                                                                                                                                                                          P:702.0                                     P:124.4                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                          P:255.0                                     P:8.5                                                                                                                                                                                                                                                                                                                                                                                                                                

  Vernon et al. (29)     28 y                     CKLT                                             18 m                   Y                                          N                                                    P: 6965 ± 1638                              P:234 ± 100                   Restricted                                             Not\                                   Optic neuropathy, leukoencephalopathy                                                                                                Stable visual function, tremor persists                                Y      N                                             Worsening generalized debility          Able to\
                                                                                                                                                                                                                                                                                                                                                           restricted                                                                                                                                                                                                                                                                                                                                      walk

  Spada et al. (28)      3 y                      Whole LT                                         12 y                   Y                                          N                                                    P: sustained (\~80%) and stable reduction   0.8                           1.5                                                    Normal intellectual development        N                                                                                                                                    Y                                                                      NA     NA                                                                                    

                         9 m                      Split-LT                                         2 y                    Y                                          N                                                    P:124.4                                     P:43.5                        0.8                                                    1.8                                    Adequate neurologic development                                                                                                      N                                                                      N      NA                                            NA                                      

  Niemi et al. (18)      Mean 8.2 y (0.8--20.7)   LT[^\*^](#TN3){ref-type="table-fn"} (*n* = 6)\   Mean 3.25 ± 4.2 y      Y                                          N                                                    P:1648 ± 1492                               P:305 ± 108                   1.6 (Natural protein 0.3--1.9)                         1.6 (Natural protein 0.6--1.8)         Maintained neurodevelopmental abilities                                                                                              Y (*n* = 8)                                                            N      Present in 12 patients (86%)                  Maintained or improved                  
                                                  CKLT (*n* = 8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Khanna et al. (24)     28 y                     OLT (domino donor)                               11 m                   Y                                          N                                                    P:445.9 ± 257.0                             P:333.3\                      Y                                                      1.0--1.9 (liberalized)                 Increasing neurologic disability                                                                                                     NA                                                                     \>60   51.0 ± 12.1[^†^](#TN4){ref-type="table-fn"}   Altered gait, and slower speech         NA
                                                                                                                                                                                                                                                                      ± 117.7                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                          U:5277 ± 1968                               U:1068 ± 384                                                                                                                                                                                                                                                                                                                                                                                                                         

  Sakamoto et al. (20)   7 y                      LDLT (*n* = 13)                                  4--16 y (mean 8.1 y)   0                                          0                                                    P: \~75--240 (mean)                         P: \~5--170 (mean)            1.2                                                    Less                                   41                                                                                                                                   53                                                                     N      N                                             −2.0                                    −2.0

                         5 y                                                                                              3                                          0                                                                                                                              0.7                                                    Less                                   43                                                                                                                                   48                                                                     N      N                                             −3.1                                    −2.0

                         1 y                                                                                              3                                          0                                                                                                                              1.5                                                    1.65--1.8                              49                                                                                                                                   54                                                                     N      N                                             −3.0                                    −2.0

                         8 m                                                                                              1                                          0                                                                                                                              1.2                                                    1.3                                    NA                                                                                                                                   32                                                                     N      N                                             −2.8                                    −0.2

                         11 m                                                                                             3                                          1                                                                                                                              0.9                                                    1.5                                    55                                                                                                                                   48                                                                     N      N                                             −1.4                                    −1.8

                         5 y                                                                                              5                                          5                                                                                                                              1.7                                                    0.95                                   NA                                                                                                                                   23                                                                     N      N                                             −4.3                                    −4.4

                         10 m                                                                                             2                                          0                                                                                                                              1.5                                                    1.0--1.5                               63                                                                                                                                   55                                                                     N      N                                             −2.5                                    −1.3

                         12 m                                                                                             2                                          0                                                                                                                              0.7                                                    1.0--1.5                               57                                                                                                                                   42                                                                     N      N                                             −2.5                                    −1.7

                         9 m                                                                                              3                                          2                                                                                                                              1.3                                                    1.0                                    NA                                                                                                                                   NA                                                                     N      N                                             −3.2                                    −0.6

                         8 m                                                                                              1                                          0                                                                                                                              1.3                                                    1.2                                    NA                                                                                                                                   NA                                                                     N      N                                             1.5                                     0.8

                         2 y                                                                                              3                                          0                                                                                                                              1.0                                                    1.0--1.5                               60                                                                                                                                   54                                                                     Y      Y[^※^](#TN5){ref-type="table-fn"}             −3.6                                    −1.9

                         2 y                                                                                              5                                          1                                                                                                                              2.0                                                    1.0--1.5                               NA                                                                                                                                   NA                                                                     N      N                                             −3.6                                    −3.2

                         10 m                                                                                             1                                          0                                                                                                                              1.5                                                    Not restricted                         70                                                                                                                                   NA                                                                     N      N                                             −0.7                                    0.0

  Critelli et al. (23)   6.6 y                    Kidney/split liver                               3.1 y                  Y                                          N                                                    P: 745 (mean)                               P: 154.9 (mean)               1.6--2.0                                               1                                      NA                                                                                                                                   NA                                                                     56     78                                            Mild                                    NA

                         21.6 y                   CKLT                                             1.6 y                  Y                                          N                                                                                                                              1.45--1.75                                             1.0--1.1                                                                                                                                                                                                                                           40     70                                            Extremely low to borderline             

                         7.4 y                    CKLT                                             4.1 y                  Y                                          N                                                                                                                              1.6--2.0                                               1.43                                                                                                                                                                                                                                               66.2   142                                           Moderate to severe                      

                         15.5 y                   CKLT                                             11.6 y                 Y                                          N                                                                                                                              1.3                                                    0.76--0.95                                                                                                                                                                                                                                         40     68[^§^](#TN6){ref-type="table-fn"}            Mild                                    

                         9.4 y                    CKLT                                             3.6 y                  Y                                          N                                                                                                                              0.98--1.18                                             1.3--1.5                                                                                                                                                                                                                                           65     88                                            No formal testing                       

                         1.9 y                    OLT                                              1 y                    Y                                          N                                                                                                                              0.83                                                   1.0--1.2                                                                                                                                                                                                                                           96.8   128                                           Borderline                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*NA, not available; OLT, orthotopic liver transplantation; LDLT, living donor liver transplantation*.

*72 days post-transplantation, MRI with diffusion-weighted imaging of brain demonstrated an acute lesion in the right globus pallidus but has never manifested clinical signs of extrapyramidal tract disease. Subsequent MRI 18 months later showed resolution of the basal ganglion lesion*.

*Died of sepsis on postoperative day 44*.

*One underwent liver retransplantation because of hepatic artery thrombosis*.

*The postoperative period was complicated by acute kidney injury. The renal function improved progressively*.

*Acute renal failure occurred after using contrast medium for endoscopic retrograde cholangiopancreatography*.

*Underwent a renal biopsy 17 months after CLKT, which showed mild tubulointerstitial injury*.

Improvement in Metabolic Decompensation and Protein Diet After LT
-----------------------------------------------------------------

Koichi Kamei et al. ([@B16]) attempted to reduce MMA levels in plasma by preoperative dialysis to reduce the risk of postoperative metabolic decompensation. The results showed that, although the MMA level was significantly reduced (*n* = 10), different degrees of acidosis still occurred (*n* = 3), and one patient died (*n* = 1). It was obvious that dialysis failed to produce satisfactory results. LT, on the other hand, can quickly relieve the state of metabolic decompensation, and the recurrence rate during follow-up was significantly reduced ([@B17]).

At present, it has been confirmed by many reports that metabolic crisis recurrence can be eliminated in patients following transplant and more than 80% no longer have metabolic decompensation and acidosis, and the frequency is reduced in the remaining patients (the follow-up time ranges from 2 m to 16 y) ([@B18]--[@B20]). The state of lethargy was also completely eliminated according to Morioka et al. ([@B15]). Plasma and urine MMA levels steadily decreased to different degrees, and some reached as high as 90%, even with increased protein intake ([@B15], [@B18]--[@B24]). However, MMA levels are still more than 100 times or even 1,000 times higher than those of normal people ([@B25]) and are concentrated mainly in extrahepatic tissues ([@B26]). The concentration of MMA in cerebrospinal fluid (CSF) was not corrected after LT ([@B27]). Almost all patients still maintained L-carnitine supplementation to correct metabolic disorders. For the children who suffered neonatal-onset MMA and received early LT (*n* = 2), there was no metabolic decompensation, and the plasma MMA concentration continued to decline steadily after LT. One case was followed up for 12 years ([@B28]).

Most patients still maintain a low protein diet after surgery, while more than 70% have increased total protein intake, and two patients even have no restrictions ([@B20], [@B29]). The latest research suggests that acidosis status is significantly improved over the perioperative period by implementing a strategy of carbohydrate minimization with gradual but early lipid and protein introduction ([@B23]).

Improvement in Neurological Damage and Physical Retardation After LT
--------------------------------------------------------------------

Due to the accumulation of MMA in the brain and recurrent acidosis, the manifestations of MMA in patients often include physical and neurodevelopmental disorders ([@B30]). The reported data showed that \~25--65% of the patients suffered developmental delay, 30--45% suffered motor dysfunction ([@B1]), and approximately half of the patients suffered mental retardation ([@B7]). Sakamoto et al. ([@B20]), reported that the mean developmental quotient (DQ) levels of children were 51 ± 9 and 50 ± 5 (*P* = 0.65) before and after living donor liver transplantation (LDLT), respectively, and no further deterioration occurred after LT (*n* = 13) ([@B20]). The patient\'s nervous system damage was partially ameliorated, even if the acute exacerbation of chronic bilateral optic neuropathy occurred shortly after surgery, and the situation improved later and remained stable ([@B29]) (*n* = 1). MRI of the brain of one patient who had never manifested clinical signs of extrapyramidal tract disease demonstrated an acute lesion in the right globus pallidus on postoperative day 72, and subsequent MRI 18 months later showed resolution of the basal ganglion lesion ([@B27]). In a special case, acute neurological deterioration occurred in the 5th year after LT, characterized by sudden changes in consciousness, aphasia, and hypotonia. The MRI results showed bilateral basal ganglion symmetry (*n* = 1) ([@B25]). Studies have shown that the concentration of MMA levels in CSF may remain high for several months, and even several years, after LT, which can lead to basal ganglia damage, dyskinesia, sensory neurological deafness, and other neurological complications ([@B21], [@B27], [@B29]). Patients were more likely to have seizure episodes or persistent tremors ([@B29]) in the perioperative period, which is probably a response to antibiotics and antifungal therapy after transplantation ([@B24]).

Due to short-term follow-up, most articles did not mention improvement in developmental status. For others, their developmental delay was maintained or improved. The height of most patients was significantly improved. The effect was even better when LT was performed within 1 year of age, and physical development could be restored to a normal range within 2.5 years following LT and was similar to the height of normal children of the same age group (*n* = 14) ([@B18]). In a study with an average follow-up of 8.1 years, the standard deviation (SD) of height of 77% (10/13) of patients improved, although it did not catch up with the age-matched normal value ([@B20]). Some children also showed improved athletic, learning, and social abilities, including normal schooling ([@B18], [@B25]).

Improvement in Renal Insufficiency After LT
-------------------------------------------

The accumulation of MMA can also cause visible damage to other organs, especially the kidney. By undergoing CKLT, most patients with pre-existing renal dysfunction recovered. However, Sakamoto et al. ([@B20]) reported a case with renal dysfunction (creatinine level rising) before LT. The renal function of the patient failed to recover after LT, and acute renal failure occurred after using contrast medium for endoscopic retrograde cholangiopancreatography. Some patients exhibited progressive renal insufficiency even after surgery due to the natural history of the disease or possibly even accelerated by taking immunosuppressive drugs which can cause damage to kidney ([@B24], [@B28], [@B31]).

In summary, transplantation can prevent patients with MMA from undergoing a metabolic crisis. Urine and plasma MMA levels are significantly reduced, and quality of life is significantly improved after LT. However, it cannot completely cure the disorder. MMA levels are still much higher than normal after LT, and patients still require metabolic-correcting medication as a long-term treatment. In addition, surgery cannot help patients completely avoid renal dysfunction and improve neurological complications (for more details, see [Table 1](#T1){ref-type="table"}).

Discussion {#s4}
==========

Most of the metabolic conversion of propionate occurs in the liver, therefore, LT can help the body regain normal functioning enzymes, thus improving metabolic capacity ([@B32]). With sophisticated transplantation techniques and perioperative management experience, most issues related to high mortality caused by surgery have been resolved. At present, organ transplantation has become an effective treatment for isolated MMA.

For Metabolic Decompensation and Protein Dietary
------------------------------------------------

Metabolic crisis is a fainting episode caused by a sudden worsening of metabolic decompensation for MMA patients ([@B15]). According to current reports, compared with traditional diet and medical treatment, LT can quickly alleviate metabolic decompensation of patients with MMA and basically prevent the recurrence of metabolic crisis. For infants with severe MMA, LT is highly recommended ([@B33]). However, because the genetic defect of the disease is expressed in multiple organs of the body, the metabolite level is still higher than normal even after LT. The concentrations of MMA in the CFS was not corrected according to the study. It is reasonable to assume that metabolites existing in brain are difficult to transported across the blood brain barrier.

Although dietary restriction cannot totally return to normal, relaxed dietary protein restriction with appropriate amount of natural protein can safely occur in some patients. Some medical professionals believe that because excessive restriction on protein intake may lead to a lack of essential amino acids and cause complications, an appropriate protein diet may be helpful to control MMA ([@B18]). Therefore, nutritional management is critical to optimizing the outcomes of MMA patients who are metabolically brittle. Multiple patient- and graft-related factors require us to individualize and adjust medical and nutritional support. A proposed diagnostic and management guideline of MMA/PA was carried out by worldwide experts recently and recommendations about dietary management were included ([@B1]). Additional long-term follow-up under close monitoring is required, and the recommended dietary allowance of total protein intake should be practiced.

For Neurological and Developmental Delay
----------------------------------------

The widespread distribution of metabolites in the central nervous system has direct neurotoxicity and can induce behavioral abnormalities and seizures in a rat model ([@B22], [@B34]). The basal ganglia of patients with severe MMA are prone to involvement. MRI is generally characterized by demyelination of white matter and abnormal signals in basal ganglia, which were caused by mitochondrial energy metabolism disorders ([@B25]). A study found that the basal ganglia have high energy requirements in childhood ([@B35]). Therefore, as brain energy metabolism is impaired, the brain is more vulnerable to damage.

Postoperative DQ and other results indicate that slow development still existed and early transplantation was better for children\'s physical development. One possible reason is that growth retardation is associated with insufficient protein intake and energy, repeated acidosis or vomiting ([@B36]). Therefore, early LT is recommended, especially within 1 year of age ([@B28]). LT can increase patient tolerance to natural protein, thus increasing the intake of protein in diet, and can provide a stable condition, preventing the onset of acidosis to promote physical development. While some patients with MMA still have persistent damage to the nervous system after surgery. It has been reported that newly synthesized propionyl-CoA in the brain leads to continuous accumulation of MMA, and it is difficult for metabolites already present in the brain to break through the blood-brain barrier and flow out of the CSF ([@B27]). Since the MMA levels in the brain after LT may still be high, toxic effects on the brain still exist. Potentially sustained synthesis of MMA in the sac is considered a permanent risk factor for metabolic crisis ([@B22], [@B27]).

For Renal Damage
----------------

A study with a mouse model suggested that mitochondrial dysfunction in the proximal tubules of the kidney is an important pathogenic mechanism of MMA-related renal disease ([@B37]). MMA patients with long-term survival may have renal complications due to progressive tubulointerstitial injury ([@B38]). It has been reported in the literature that LT should be performed as early as possible to obtain normal renal function ([@B19]). However, for patients during the disease progression period, postoperative renal function might continue to deteriorate. For patients with preoperative chronic kidney disease (especially at estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73 m^2^), CKLT is effective and recommended ([@B18]). While renal function remained unrecoverable or deteriorated in some patients despite a low-protein diet and appropriate medications after transplantation, which may be related to the nephrotoxicity of immunosuppressive agents, such as FK506 ([@B39]--[@B41]). To date, there are no consensus and guidelines on immunosuppression regimens. But it is reasonable to infer that we can adjust the immunosuppressive regimen such as postponing the administration time for patients with pre-existing renal insufficiency to slow down the progress to renal failure. This protocol has been carried out by our center and the shot-time outcome came out to be a success. Close long-term monitoring of postoperative renal function and strict individualized immunosuppressive therapy are extremely important ([@B42]). However, since most MMA patients have low muscle mass and are children, the serum creatinine, and calculated eGFR cannot accurately reflect real renal function ([@B43]). A new indicator that can accurately represent renal function of children with MMA needs to be established to avoid kidney transplantation in the future.

Conclusion {#s5}
==========

It is important to recognize in our review that LT is a valuable option for MMA patients and has gained some favorable prognosis, though it does not bring about a complete cure. In the future, research on how to reverse neurological damage needs to be conducted to further improve the efficacy of transplantation. Further understanding of the correlation between disease severity, procedure and outcomes will help us determine the individualized type and optimal timing of transplantation.
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CLKT

:   Combined liver-kidney transplantation

CSF

:   Cerebrospinal fluid

LDLT

:   Living donor liver transplantation

LT

:   Liver transplantation

MCM

:   Methylmalonyl-CoA mutase

MMA

:   Methylmalonic academia

OLT

:   Orthotopic liver transplantation.
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